Payment overview · 2025
General Payments
$712.66
33 reported records · 15 companies
Healthcare provider profile · identity verified
Nadeem U Kamran, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LA PORTE, IN · NPI 1275696171
Verified facts
What the public records show
CMS Open Payments records show Nadeem U Kamran, M.D. received $712.66 in general payments during 2025 across 33 reported records.
ABBVIE INC. accounted for 36.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Linzess, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Rybelsus by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $258.82 | 36.3% | 13 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $77.19 | 10.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $52.81 | 7.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.97 | 6.0% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $37.90 | 5.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.59 | 4.8% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.90 | 4.8% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $28.64 | 4.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $27.78 | 3.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.48 | 3.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.85 | 3.1% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $21.63 | 3.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $21.13 | 3.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.63 | 2.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.34 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $712.66 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $167.94 | 7 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $90.88 | 6 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $77.19 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $49.63 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $37.90 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.59 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $33.90 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $28.64 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.48 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| GATTEX Normalized: gattex |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $11.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 87 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 53 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
87 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
66 | 20 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
102 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
81 | 23 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2127 | 236 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1529 | 152 |
| Furosemide | Furosemide | 1514 | 174 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1345 | 163 |
| Gabapentin | Gabapentin | 1317 | 169 |
| Sertraline Hcl | Sertraline Hcl | 1239 | 97 |
| Eliquis | Apixaban | 1138 | 101 |
| Memantine Hcl | Memantine Hcl | 1004 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 983 | 116 |
| Donepezil Hcl | Donepezil Hcl | 822 | 56 |
| Lisinopril | Lisinopril | 805 | 101 |
| Metoprolol Tartrate | Metoprolol Tartrate | 804 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 762 | 96 |
| Clopidogrel | Clopidogrel Bisulfate | 694 | 64 |
| Montelukast Sodium | Montelukast Sodium | 665 | 111 |
| Losartan Potassium | Losartan Potassium | 638 | 82 |
| Tamsulosin Hcl | Tamsulosin Hcl | 634 | 83 |
| Allopurinol | Allopurinol | 625 | 45 |
| Potassium Chloride | Potassium Chloride | 615 | 78 |
| Carvedilol | Carvedilol | 589 | 81 |
| Spironolactone | Spironolactone | 557 | 49 |
| Metformin Hcl | Metformin Hcl | 509 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 476 | 58 |
| Omeprazole | Omeprazole | 461 | 54 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 448 | 68 |
| Trazodone Hcl | Trazodone Hcl | 436 | 74 |
| Hydralazine Hcl | Hydralazine Hcl | 433 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 401 | 43 |
| Ropinirole Hcl | Ropinirole Hcl | 378 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 375 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 373 | 35 |
| Finasteride | Finasteride | 337 | 34 |
| Pregabalin | Pregabalin | 306 | 31 |
| Famotidine | Famotidine | 299 | 30 |
| Prednisone | Prednisone | 290 | 94 |
| Doxycycline Hyclate | Doxycycline Hyclate | 242 | 130 |
| Lamotrigine | Lamotrigine | 231 | 40 |
| Levetiracetam | Levetiracetam | 229 | 23 |
| Mirtazapine | Mirtazapine | 228 | 31 |
| Tramadol Hcl | Tramadol Hcl | 199 | 44 |
| Amiodarone Hcl | Amiodarone Hcl | 184 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 176 | 23 |
| Midodrine Hcl | Midodrine Hcl | 175 | 28 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 169 | 13 |
| Alprazolam | Alprazolam | 166 | 19 |
| Meclizine Hcl | Meclizine Hcl | 165 | 19 |
| Bumetanide | Bumetanide | 151 | 17 |
| Warfarin Sodium | Warfarin Sodium | 148 | 11 |
| Risperidone | Risperidone | 143 | 11 |
| Buspirone Hcl | Buspirone Hcl | 141 | 27 |
| Galantamine Hbr | Galantamine Hbr | 140 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 60 |
| Tradjenta | Linagliptin | 139 | 12 |
| Lorazepam | Lorazepam | 134 | 58 |
| Quetiapine Fumarate | Quetiapine Fumarate | 133 | 21 |
| Clonazepam | Clonazepam | 132 | 17 |
| Baclofen | Baclofen | 130 | 13 |
| Mounjaro | Tirzepatide | 128 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 128 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 122 | 22 |
| Celecoxib | Celecoxib | 121 | 31 |
| Rivastigmine | Rivastigmine Tartrate | 119 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 118 | 56 |
| Cephalexin | Cephalexin | 115 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 29 |
| Latanoprost | Latanoprost | 113 | 27 |
| Cilostazol | Cilostazol | 110 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 104 | 20 |
| Digoxin | Digoxin | 104 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 21 |
| Xarelto | Rivaroxaban | 102 | 19 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 101 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 101 | 18 |
| Dexamethasone | Dexamethasone | 93 | 44 |
| Entresto | Sacubitril/Valsartan | 93 | 13 |
| Insulin Lispro | Insulin Lispro | 88 | 18 |
| Creon | Lipase/Protease/Amylase | 87 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 87 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | 13 |
| Glimepiride | Glimepiride | 83 | 16 |
| Clonidine Hcl | Clonidine Hcl | 82 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 81 | 18 |
| Rybelsus | Semaglutide | 81 | 23 |
| Alendronate Sodium | Alendronate Sodium | 79 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 77 | 32 |
| Myrbetriq | Mirabegron | 76 | suppressed |
| Ibuprofen | Ibuprofen | 74 | 18 |
| Metolazone | Metolazone | 72 | 12 |
| Glipizide | Glipizide | 71 | 20 |
| Torsemide | Torsemide | 71 | suppressed |
| Bupropion Xl | Bupropion Hcl | 70 | 14 |
| Methotrexate | Methotrexate Sodium | 69 | suppressed |
| Primidone | Primidone | 69 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 68 | 38 |
| Colesevelam Hcl | Colesevelam Hcl | 67 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 67 | suppressed |
| Ertapenem | Ertapenem Sodium | 67 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 12 |
| Nystatin | Nystatin | 66 | 39 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 20 |
| Trulicity | Dulaglutide | 66 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 65 | 30 |
| Loperamide | Loperamide Hcl | 63 | 35 |
| Dicyclomine Hcl | Dicyclomine Hcl | 62 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | suppressed |
| Ezetimibe | Ezetimibe | 61 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 24 |
| Lubiprostone | Lubiprostone | 61 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 60 | 14 |
| Fluconazole | Fluconazole | 59 | 32 |
| Olanzapine | Olanzapine | 59 | suppressed |
| Topiramate | Topiramate | 59 | suppressed |
| Atenolol | Atenolol | 58 | suppressed |
| Ranolazine Er | Ranolazine | 58 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 57 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 57 | suppressed |
| Febuxostat | Febuxostat | 56 | suppressed |
| Jardiance | Empagliflozin | 56 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 56 | 18 |
| Solifenacin Succinate | Solifenacin Succinate | 56 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 55 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 54 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 54 | suppressed |
| Roflumilast | Roflumilast | 54 | suppressed |
| Simvastatin | Simvastatin | 54 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 53 | suppressed |
| Linzess | Linaclotide | 53 | 11 |
| Terazosin Hcl | Terazosin Hcl | 52 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 51 | 11 |
| Clonidine | Clonidine | 50 | suppressed |
| Folic Acid | Folic Acid | 50 | suppressed |
| Gemtesa | Vibegron | 49 | suppressed |
| Sucralfate | Sucralfate | 49 | 12 |
| Glipizide Er | Glipizide | 47 | 15 |
| Fenofibrate | Fenofibrate,micronized | 46 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 45 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 14 |
| Ozempic | Semaglutide | 45 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 45 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Azithromycin | Azithromycin | 43 | 25 |
| Ceftriaxone | Ceftriaxone Sodium | 43 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 40 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 40 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 40 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 13 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 39 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 39 | 16 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 38 | 11 |
| Diazepam | Diazepam | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 18 |
| Valsartan | Valsartan | 35 | suppressed |
| Glyburide | Glyburide | 34 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 34 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 33 | suppressed |
| Meloxicam | Meloxicam | 33 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 19 |
| Nitroglycerin | Nitroglycerin | 32 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Anastrozole | Anastrozole | 31 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 31 | 26 |
| Ketoconazole | Ketoconazole | 31 | 12 |
| Xifaxan | Rifaximin | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 29 | suppressed |
| Daptomycin | Daptomycin | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | 15 |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Colchicine | Colchicine | 28 | 11 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 28 | suppressed |
| Ursodiol | Ursodiol | 28 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 27 | suppressed |
| Lactulose | Lactulose | 27 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 11 |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Entacapone | Entacapone | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | 11 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 25 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 15 |
| Sotalol | Sotalol Hcl | 22 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 21 | 21 |
| Cholestyramine | Cholestyramine (With Sugar) | 21 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Amantadine | Amantadine Hcl | 20 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Cholestyramine Light | Cholestyramine | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 16 |
| Bethanechol Chloride | Bethanechol Chloride | 16 | suppressed |
| Kerendia | Finerenone | 16 | suppressed |
| Leflunomide | Leflunomide | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Verquvo | Vericiguat | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 12 |
| Cefepime Hcl | Cefepime Hcl | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Neupro | Rotigotine | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Rayaldee | Calcifediol | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $712.66 · 33 records | ABBVIE INC. | AIRSUPRA, BREZTRI, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, FANAPT, FARXIGA, FREESTYLE LIBRE 3, FUROSCIX, GATTEX, LINZESS, REXULTI, SPRAVATO, TRELEGY ELLIPTA, VRAYLAR, Wegovy, YUPELRI, ZENPEP | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error